Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767807 | 0.84 | NPSR1 (0.74) | NPSR1HSP90AA1ALDH1A1KMT2AMAPT | |
| SCHEMBL4768044 | 0.79 | HPGD (0.52) | HPGDHSP90AA1ALDH1A1KMT2AMEN1 | |
| SCHEMBL10107755 | 0.75 | HSP90AA1 (0.66) | HPGDHSP90AA1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4791474 | 0.75 | ALDH1A1 (0.61) | HPGDNPSR1HSP90AA1ALDH1A1KMT2A | |
| SCHEMBL95064 | 0.74 | HPGD (0.65) | HPGDNPSR1HSP90AA1ALDH1A1KMT2A | |
| SCHEMBL14497659 | 0.74 | GAA (0.59) | HPGDNPSR1ALDH1A1KMT2AMAPT | |
| SCHEMBL4775048 | 0.73 | GAA (0.70) | HPGDNPSR1ALDH1A1MAPTGAA | |
| SCHEMBL4777536 | 0.73 | GAA (0.58) | HPGDNPSR1ALDH1A1KMT2AMAPT | |
| SCHEMBL4768069 | 0.71 | GAA (0.64) | HPGDNPSR1ALDH1A1KMT2AMAPT | |
| SCHEMBL4774743 | 0.71 | ALDH1A1 (0.60) | HPGDNPSR1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | HPGD 2681/4885NPSR1 4395/4885HSP90AA1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.